Clinical Trials
34 trialsVorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
PEDS-PLAN
Milton S. Hershey Medical Center
NYMC195
New York Medical College
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Thomas Jefferson University
MIBG With Dinutuximab +/- Vorinostat
New Approaches to Neuroblastoma Therapy Consortium
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
M.D. Anderson Cancer Center
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
OPTIMUM
Jubilant DraxImage Inc.
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
National Cancer Institute (NCI)
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
National Cancer Institute (NCI)
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
Johns Hopkins All Children's Hospital
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Stanford University
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Duke University
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
National Taiwan University Hospital
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Duke University
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
National Cancer Institute (NCI)